keyword
MENU ▼
Read by QxMD icon Read
search

Anti-VEGF

keyword
https://www.readbyqxmd.com/read/28527480/safety-and-effectiveness-of-cataract-surgery-with-simultaneous-intravitreal-anti-vegf-in-patients-with-previously-treated-exudative-age-related-macular-degeneration
#1
Manuel Sousa Falcão, Paulo Freitas-Costa, João Nuno Beato, João Pinheiro-Costa, Amândio Rocha-Sousa, Ângela Carneiro, Elisete Maria Brandão, Fernando Falcão-Reis
INTRODUCTION: To evaluate the safety and impact on visual acuity, retinal and choroidal morphology of simultaneous cataract surgery and intravitreal anti-vascular endothelial growth factor on patients with visually significant cataracts and previously treated exudative age-related macular degeneration. MATERIAL AND METHODS: Prospective study, which included 21 eyes of 20 patients with exudative age-related macular degeneration submitted to simultaneous phacoemulsification and intravitreal ranibizumab or bevacizumab...
February 27, 2017: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/28527040/fundamental-principles-of-an-anti-vegf-treatment-regimen-optimal-application-of-intravitreal-anti-vascular-endothelial-growth-factor-therapy-of-macular-diseases
#2
REVIEW
Paolo Lanzetta, Anat Loewenstein
BACKGROUND: Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is now considered the gold standard for the treatment of various retinal disorders. As therapy has evolved, so too have the treatment regimens employed by physicians in clinical practice; however, visual outcomes observed in the real world have typically not reflected those reported in clinical trials. Possible reasons for this include a lack of consensus on treatment regimens and a lack of clarity about what the aims of treatment should be...
May 19, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28524152/-vascular-endothelial-growth-factor-inhibitors-in-the-treatment-of-neovascular-age-related-macular-degeneration
#3
I N Dyakov, S K Zyryanov
Neovascular age-related macular degeneration (AMD) is the leading cause of vision loss in older patients. An important role in angiogenesis is played by regulatory mechanisms (an increase in the number of proliferating endothelial and stromal cells and morphological alterations in the vascular network) induced by factors from the vascular endothelial growth factor (VEGF) family. Since 2006, the key treatment of neovascular AMD includes agents that inhibit the activity of VEGF. This review covers the effectiveness and safety of the use of anti-VEGF agents in neovascular AMD patients...
2017: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/28520639/wrinkled-vascularized-retinal-pigment-epithelium-detachment-prognosis-after-intravitreal-anti-vegf-therapy
#4
Delphine Lam, Oudy Semoun, Rocio Blanco-Garavito, Camille Jung, Diem T Nguyen, Eric H Souied, Gerard Mimoun
BACKGROUND/PURPOSE: Neovascular age-related macular degeneration (nAMD) is frequently associated with vascularized pigment epithelial detachment (v-PED). We observed a peculiar characteristic of v-PED characterized by small lacy folds of the retinal pigment epithelium, appearing as a wrinkled PED (w-PED) on spectral domain optical coherence tomography (SD-OCT). Our purpose was to describe the visual prognosis and number of intravitreal injections in w-PED compared with non-w-PED. METHODS: In this retrospective, case-control series, we reviewed retrospectively medical records of 52 eyes of 51 patients who were consecutively included between November 1 and 30, 2015 with a previous minimum 3-year follow-up...
May 16, 2017: Retina
https://www.readbyqxmd.com/read/28513493/inflammatory-choroidal-neovascularization-in-indian-eyes-etiology-clinical-features-and-outcomes-to-anti-vascular-endothelial-growth-factor
#5
Rupak Roy, Kumar Saurabh, Aditya Bansal, Amitabh Kumar, Anindya Kishore Majumdar, Swakshyar Saumya Paul
BACKGROUND AND OBJECTIVES: The aim was to study the clinical profile of inflammatory choroidal neovascularization (CNV) and its treatment response to intravitreal bevacizumab or ranibizumab on pro re nata (PRN) basis in Indian eyes. MATERIALS AND METHODS: This was a retrospective case series of consecutive patients with inflammatory CNV treated with anti-vascular endothelial growth factor (anti-VEGF) in a tertiary eye care center in Eastern India between 2009 and 2014...
April 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28512425/long-term-follow-up-of-polypoidal-choroidal-vasculopathy-secondary-to-angioid-streaks-treated-by-intravitreal-aflibercept-and-ranibizumab
#6
James G Wong, Katherine Yu Qian
PURPOSE: Angioid streaks (AS) are dehiscences in Bruch's membrane that may be idiopathic or associated with numerous systemic illnesses. Polypoidal choroidal vasculopathy (PCV) is an underdiagnosed exudative chorioretinopathy often characterised by serosanguineous detachments of the pigmented epithelium. The use of the anti-VEGF agents ranibizumab and aflibercept in the management of PCV secondary to AS has not been previously documented. We report 3 patients with active PCV secondary to AS, 1 of which had a family history of PCV secondary to AS, not previously reported in the literature...
January 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28508241/resource-use-and-real-world-outcomes-for-ranibizumab-treat-and-extend-for-neovascular-age-related-macular-degeneration-in-the-uk-interim-results-from-terra
#7
Yit Yang, Louise Downey, Hemal Mehta, Bushra Mushtaq, Niro Narendran, Nishal Patel, Praveen J Patel, Filis Ayan, Kara Gibson, Franklin Igwe, Pete Jeffery
INTRODUCTION: Ranibizumab is an inhibitor of vascular endothelial growth factor-A (anti-VEGF) approved for the treatment of neovascular age-related macular degeneration (nAMD). The treat and extend (T&E) regimen can potentially reduce the burden of clinic visits compared with a pro re nata (PRN) regimen. Retrospective, interim analyses of clinical effectiveness, treatment and resource use patterns were conducted using real-world data in England and Wales from the TERRA study. METHODS: Two cohorts, those switching from a PRN to a T&E regimen ('prior PRN') and those initiating ranibizumab on the T&E regimen as their first anti-VEGF therapy ('anti-VEGF-naïve') were enrolled in TERRA...
May 15, 2017: Ophthalmology and Therapy
https://www.readbyqxmd.com/read/28503435/evaluation-of-hyperreflective-foci-as-a-prognostic-factor-of-visual-outcome-in-retinal-vein-occlusion
#8
Bin Mo, Hai-Ying Zhou, Xuan Jiao, Feng Zhang
AIM: To evaluate the potential role of hyperreflective foci (HF) as a prognostic indicator of visual outcome in patients with macular edema (ME) due to retinal vein occlusion (RVO). METHODS: We retrospectively reviewed 50 eyes of 50 patients with ME due to ischemic central retinal vein occlusion (CRVO), non-ischemic CRVO and branch retinal vein occlusion (BRVO) who were treated with anti-vascular endothelial growth factor (anti-VEGF) at Beijing Tongren Eye Center from January 2013 to July 2016...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28499163/the-diabetic-retinopathy-barometer-study-global-perspectives-on-access-to-and-experiences-of-diabetic-retinopathy-screening-and-treatment
#9
D Cavan, L Makaroff, J da Rocha Fernandes, M Sylvanowicz, P Ackland, J Conlon, D Chaney, A Malhi, J Barratt
AIM: To assess the level of awareness, prevention and treatment of Diabetic Eye Disease (DED) comprising Diabetic Retinopathy (DR) and Diabetic Macula Edema (DME) retinopathy among adults with diabetes and health professionals. METHODS: The Diabetic Retinopathy Barometer Study consisted of a qualitative study, which consisted of semi-structured interviews, and a quantitative study using online surveys for adults with diabetes and for health professionals. RESULTS: A total of 4340 adults with diabetes and 2329 health professionals participated in the surveys...
April 4, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28499051/safety-and-efficacy-of-ziv-aflibercept-in-the-treatment-of-refractory-diabetic-macular-edema
#10
Mohammed Ashraf, Hassan El Kayal, Ahmed A R Souka
BACKGROUND AND OBJECTIVE: To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of refractory diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective case series looking at the safety of ziv-aflibercept in patients with DME refractory to previous anti-vascular endothelial growth factor (VEGF) therapy. Detailed ophthalmologic examination, best-corrected visual acuity, and optical coherence tomography measurements were performed pre-switch, as well as at each monthly follow-up visit...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28496299/response-of-eyes-with-age-related-macular-degeneration-to-anti-vegf-drugs-and-implications-for-therapy-planning
#11
Noriko Miyamoto, Michiko Mandai, Hiroshi Kojima, Takanori Kameda, Masataka Shimozono, Akihiro Nishida, Yasuo Kurimoto
PURPOSE: To evaluate the response to and dependence on aflibercept or ranibizumab in patients with age-related macular degeneration (AMD). METHODS: We retrospectively reviewed AMD patients who received induction therapy with aflibercept or ranibizumab for the following parameters: whether complete resolution of the retinal fluid ("good response") was achieved and whether recurrence was observed within 3 months ("dependent") after the induction treatment. With aflibercept treatment, treatment-naïve eyes with a good response/non-dependence were recommended a pro re nata regimen, and other eyes were recommended a proactive bimonthly regimen, followed by monitoring of visual acuity (VA) for 12 months...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28494491/topical-delivery-of-anti-vegf-drugs-to-the-ocular-posterior-segment-using-cell-penetrating-peptides
#12
Felicity de Cogan, Lisa J Hill, Aisling Lynch, Peter J Morgan-Warren, Judith Lechner, Matthew R Berwick, Anna F A Peacock, Mei Chen, Robert A H Scott, Heping Xu, Ann Logan
Purpose: To evaluate the efficacy of anti-VEGF agents for treating choroidal neovascularization (CNV) when delivered topically using novel cell-penetrating peptides (CPPs) compared with delivery by intravitreal (ivit) injection. Methods: CPP toxicity was investigated in cell cultures. Ivit concentrations of ranibizumab and bevacizumab after topical administration were measured using ELISA. The biological efficacy of topical anti-VEGF + CPP complexes was compared with ivit anti-VEGF injections using an established model of CNV...
May 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28492860/baseline-factors-associated-with-6-month-visual-acuity-and-retinal-thickness-outcomes-in-patients-with-macular-edema-secondary-to-central-retinal-vein-occlusion-or-hemiretinal-vein-occlusion-score2-study-report-4
#13
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Jacqueline King, Andrew N Antoszyk, Mark A Peters, Michael Tolentino
Importance: Macular edema (ME) is the leading cause of decreased visual acuity (VA) associated with retinal vein occlusion (RVO). Identifying factors associated with better outcomes in RVO eyes treated with anti-vascular endothelial growth factor (VEGF) therapy may provide information useful in counseling patients. Objective: To investigate baseline characteristics associated with 6-month VA and central subfield thickness (CST) outcomes in participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)...
May 9, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28492427/quantitative-optical-coherence-tomography-analysis-of-retinal-degenerative-changes-in-diabetic-macular-edema-and-neovascular-age-related-macular-degeneration
#14
Ernest V Boiko, Dmitrii S Maltsev
PURPOSE: To investigate the relationship of the pre-anti-vascular endothelial growth factor (VEGF) retinal tissue area (RTA) and optical density (ODRT) of the retinal optical slice portion located in the central subfield, and their ratio (RTA/ODRT), in the presence of diabetic macular edema or of inraretinal cystic fluid in neovascular age-related macular degeneration, to central retinal thickness and best-corrected visual acuity after anti-VEGF treatment with ME resolution. METHODS: The optical coherence tomography images and medical records of 33 patients (41 eyes) with neovascular age-related macular degeneration, 15 (21 eyes) with diabetic macular edema and 9 healthy individuals (15 eyes) were retrospectively analyzed...
May 10, 2017: Retina
https://www.readbyqxmd.com/read/28491229/-anti-vegf-therapy-for-juxtafoveolar-choroidal-neovessels-in-people-with-high-myopia-about-a-case
#15
Moulay Omar Moustaine, Foued Dellali, Abbas El Husseini, Anne-Lise Hirsch
Choroidal neovessels are a threatening complication of high myopia, accounting for 5 to 10% of cases. They require immediate treatment because of their poor prognosis. Anti-VEGF intravitreal injections are currently a new therapeutic alternative far exceeding photodynamic therapy (PDT). Nevertheless, anti-VEGF treatment algorithm for this type of neovessels remains a matter of discussion among the authors. The purpose of this study was to highlight the difficulties in managing these neovessels and to discuss the Anti-VEGF therapeutic regimen to follow...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28490886/apatinib-to-combat-egfr-tki-resistance-in-an-advanced-non-small-cell-lung-cancer-patient-with-unknown-egfr-status-a-case-report
#16
Yanmei Peng, Huijuan Cui, Zhe Liu, Daiwei Liu, Fan Liu, Yazhong Song, Hua Duan, Yuqin Qiu, Qiang Li
Lung adenocarcinoma is the most common pathological pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. In the present clinical practice, antagonists of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF)-directed therapies are widely used. In the former category, the agent erlotinib (tyrosine kinase inhibitor) has shown obvious advantages over cytotoxic therapy. Anti-VEGF therapy bevacizumab used for lung adenocarcinoma was recommended in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as first-line therapy...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28484955/ranibizumab-in-the-treatment-of-diabetic-macular-edema-a-review-of-the-current-status-unmet-needs-and-emerging-challenges
#17
REVIEW
Nikolaos Dervenis, Athanasia Maria Mikropoulou, Paris Tranos, Panagiotis Dervenis
Diabetic retinopathy (more specifically diabetic macular edema, DME) is the most common cause of loss of vision in the working population in developed countries. Anti-vascular endothelial growth factor (anti-VEGF) agents considerably changed the treatment algorithms and improved prognosis of center-involving DME. Ranibizumab was the first approved anti-VEGF agent that revolutionized DME treatment. The vast increase in the number of patients undergoing intravitreal treatment and the role of anti-VEGF pharmacotherapy as the mainstay of DME treatment have triggered several challenges...
May 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28482126/cytosolic-expression-of-functional-fab-fragments-in-e-coli-using-a-novel-combination-of-dual-sumo-expression-cassette-and-enbase-%C3%A2-cultivation-mode
#18
Faegheh Rezaie, Fatemeh Davami, Kamran Mansouri, Sulmaz Agha Amiri, Ramin Fazel, Reza Mahdian, Noushin Davoudi, Somayeh Enayati, Mohammad Azizi, Vahid Khalaj
AIMS: The E. coli expression system is highly effective in producing recombinant proteins. However, there are some limitations in this system, especially in obtaining correctly folded forms of some complex proteins such as Fab fragments. To improve the solubility and folding quality of Fab fragments, we have examined the effect of simultaneous application of a SUMO fusion tag, EnBase(®) cultivation mode and a redox mutant strain in the E. coli expression system. METHODS AND RESULTS: A bicistronic gene construct was designed to express an anti-VEGF Fab fragment as a model system...
May 8, 2017: Journal of Applied Microbiology
https://www.readbyqxmd.com/read/28473314/combined-anti-vegf-and-anti-ctla-4-therapy-elicits-humoral-immunity-to-galectin-1-which-is-associated-with-favorable-clinical-outcomes
#19
Xinqi Wu, Jingjing Li, Erin M Connolly, Xiaoyun Liao, Jing Ouyang, Anita Giobbie-Hurder, Donald Lawrence, David McDermott, George Murphy, Jun Zhou, Matthias Piesche, Glenn Dranoff, Scott Rodig, Margaret Shipp, F Stephen Hodi
The combination of anti-VEGF blockade (bevacizumab) with immune checkpoint anti-CTLA-4 blockade (ipilimumab) in a phase I study showed tumor endothelial activation and immune cell infiltration that were associated with favorable clinical outcomes in patients with metastatic melanoma. To identify potential immune targets responsible for these observations, post-treatment plasma from long-term responding patients were used to screen human protein arrays. We reported that ipilimumab plus bevacizumab therapy elicited humoral immune responses to galectin-1 (Gal-1) which exhibits pro-tumor, pro-angiogenesis, and immunosuppressive activities in 37...
May 4, 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/28472181/hypertrophic-scar-regression-is-linked-to-the-occurrence-of-endothelial-dysfunction
#20
Xi-Qiao Wang, Fei Song, Ying-Kai Liu
Most microvessels have been shown to become stenosed or completely occluded during hypertrophic scar progression. Here, we examined the morphology of capillary endothelial cells (ECs) and fibroblasts using immunofluorescence staining for CD31 and alpha-smooth muscle actin (α-SMA) and electron microscopy. In addition, ECs and fibroblasts were isolated from scar tissues, and the levels of transforming growth factor beta 1 (TGF-β1), platelet-derived growth factor (PDGF), endothelin 1 (ET-1), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were assayed using ELISAs...
2017: PloS One
keyword
keyword
35594
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"